• BLRX is trading at $2.78, down 12.03% from yesterday's close, as broader market risk-off sentiment impacts stocks.
  • This decline comes despite BioLineRx announcing new preclinical data on July 8, 2026, demonstrating strong synergistic effects between its GLIX1 asset and PARP inhibitors in a patient-derived ovarian cancer model.
  • The positive oncology trial-related update for GLIX1 was released today, contradicting the earlier report of no fresh company-specific news.